MHRA review confirms benefit/risk profile of Alteplase

MHRA review confirms benefit/risk profile of Alteplase

MHRA review confirms benefit/risk profile of Alteplase

The FINANCIAL -- On July 24, Boehringer Ingelheim received the positive news that, following an expert working group review, on behalf of the Medicines and Healthcare products Regulatory Agency has reconfirmed that the benefits of our specialist stroke medicine Alteplase, outweigh the risks, when used within its license.

This announcement confirms that patients and doctors should have full confidence in our medicine, which is supported by more than a decade of clinical experience, according to Boehringer Ingelheim.

Professor Jörg Kreuzer, Head of Cardiovascular Medicine for Boehringer Ingelheim said “Alteplase is the only approved medicine to treat acute ischaemic stroke, a disease that can have a long lasting and a profound impact on a person’s ability to walk, see, talk, feel or understand their world. The news from MHRA expert working group confirms that our medicine can play a vital role in improving the lives of patients.”